• Save
Electronic Review Systems
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

Electronic Review Systems

  • 598 views
Uploaded on

This deck was presented at the 2013 Food & Drug Law Institute's Advertising & Promotion conference. I provided advice to people responsible for the selection and/or upgrade of electronic......

This deck was presented at the 2013 Food & Drug Law Institute's Advertising & Promotion conference. I provided advice to people responsible for the selection and/or upgrade of electronic promotional review systems used in the review and approval of marketing materials for prescription products.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
598
On Slideshare
592
From Embeds
6
Number of Embeds
1

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 6

https://twitter.com 6

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Deciding on an electronic review system Dale Cooke Digitas Health
  • 2. • Faster approval times • Complete audit trail • Lower agency costs • Improved compliance 2 e-System Benefits
  • 3. • If the wrong system is implemented or the system isn’t implemented well, the costs are severe: • Cost-overruns and delays during implementation • Frustrated users • Confused agency partners • Compliance risks • Increased cost for reviewing and approving materials (both internally and from agency partners) 3 e-System Drawbacks
  • 4. Relatively Few Established Players Aprimo Veeva Vault Zinc Ahead Documentum Next Docs
  • 5. • Agency access • One log-in per agency is preferred • Automatic agenda creation • Opens job codes well before submitting projects • Audit reports • Auto-generates certain communications (approval to use, expiration notices, etc.) • Clean user interface • Maintains a library of references • Ability to integrate with other systems (procurement, print production, Digital Assessment Management (DAM)) • How are updates rolled out? 5 Key Features
  • 6. Key Features (cont’d) • Mobile access (iPad & iPhone) • Immediate accessibility of meeting markup • Ability to link associated projects (e.g., an outer envelope, cover letter, and brochure) • Automatically track expiration dates for annual review and generate renewal reminders • Support all standard web browsers and updates • Allow for integration with FDA Gateway • Accommodate multiple regions and approval processes • Deal with co-promote/joint venture partners • Understand the hosting environment and whether it can accommodate volume demands
  • 7. Reference Handling • Maintain a library of acceptable references • New references should be vetted by medical reviewer prior to system addition – Ensure this isn’t too time consuming – Avoids duplicate references • Link references to projects using them • Accommodate multiple links to and from the same claim and/or reference • Core claims documentation • Be wary of systems that link too much (weigh the costs and benefits of traceability)
  • 8. Keys to a Successful Implementation • Involve the right people in the implementation • Train at the right time (Goldilocks rule, not too soon, not too late) • Understand customization vs. configuration distinction – Avoid customization • Establish a team of champions with local/regional/departmental representation
  • 9. Dale Cooke VP/Group Director, Regulatory Review Dale Cooke is the head of the regulatory department for Digitas Health. He has worked with more than 30 pharmaceutical, biotech, and medical device clients and with Medical-Legal-Regulatory committees around the world from offices in Philadelphia, New York, San Francisco, Boston, and London. Dale advises clients on FDA enforcement actions and provides recommendations for compliance with FDA regulations, with a focus on issues involving the Internet and emerging technology. His insights have been featured in the Wall Street Journal’s Health blog, The Pink Sheet, MedAdNews, PharmExec, and others. Dale is a member of the Regulatory Affairs Professionals Society (RAPS) and the Food and Drug Law Institute (FDLI). Dale is the author of Effective Review and Approval of Digital Promotional Tactics, which is part of the FDLI primer series. He is regularly invited to speak at industry conferences on topics including FDA enforcement trends, best practices for review processes, global review practices, and pharmaceutical involvement in social media. Dale earned his B.A. in Philosophy from Southern Methodist University and an M.A. in Analytical Philosophy from the University of Arizona and studied Epidemiology and Biostatistics at Drexel University’s School of Public Health.